

Environmental and Social Data Sheet

Overview

Project Name: *IMPERIAL INNOVATIONS – LIFE SCIENCES RESEARCH*
 Project Number: *2014-0616*
 Country: *UNITED KINGDOM*
 Project Description: *Development and commercialisation of research from leading UK universities. The R&D conducted by the final beneficiaries will be particularly focused on state-of-art technology.*

EIA required: No

Project included in Carbon Footprint Exercise¹: No

Summary of Environmental and Social Assessment, including key issues and overall conclusion and recommendation

The R&D activities encompassed within this project will not materially change current R&D practices and will be carried out within existing facilities. Thus, an Environmental Impact Assessment (EIA) according to the Directive 2011/92/EU is not required.

Imperial Innovations creates, builds and invests in pioneering life sciences technologies developed from research within the 'Golden Triangle' broadly bounded by London, Cambridge and Oxford, which is home to the UK's four leading research-intensive universities. Imperial Innovations contributes to the development of novel therapies, platform technologies, devices and diagnostics that have the potential to increase the quality of life of millions of patients.

In the light of the above, the project is eligible for the Bank's financing.

Environmental and Social Assessment

Environmental Assessment

R&D facilities and practices are in compliance with national and EU relevant regulation and the promoter maintains adequate internal procedures and management practices.

EIB Carbon Footprint Exercise

Project is not included - the EIB draft Carbon Footprint Methodologies only include emissions from Investment Loans, and large allocations under Framework Loans, above the methodology thresholds.

Social Assessment, where applicable

The clinical trials which are included in the project are performed under regulated and strictly controlled conditions, in existing specialised facilities which are regularly inspected by competent authorities - EMEA in Europe and/or national equivalent bodies in the rest of the World (FDA, PMDA, SFDA,..). The recruitment of patients is performed in accordance with the European directive (2001/20/EC) and/or equivalent international regulations in case of clinical trials performed outside Europe.

¹ Only projects that meet the scope of the Pilot Exercise, as defined in the EIB draft Carbon Footprint Methodologies, are included, provided estimated emissions exceed the methodology thresholds: above 100,000 tons CO₂e/year absolute (gross) or 20,000 tons CO₂e/year relative (net) – both increases and savings.